Too little evidence to recommend Grazax for hay fever, DTB concludes

摘要

Uncertainty remains over the benefit of Grazax (grass pollen extract) for the treatment of hay fever, the latest Drug and Therapeutics Bulletin concludes after reassessing the medicine in light of recent licence changes. An original review of Grazax in the February 2008 DTB concluded that there was no convincing evidence for its use to treat hay fever (PJ, 16 February 2008, p170). Since then the product has become licensed as a disease-modifying treatment, and for the treatment of children aged five years and above with rhinoconjunctivitis due to grass pollen allergy, prompting the DTB to reconsider its value as a hay fever treatment.